Lexeo Therapeutics
Clinical trials sponsored by Lexeo Therapeutics, explained in plain language.
Develops gene therapies for cardiovascular and CNS diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene therapy trial targets rare heart disease in 10 patients Results expected Dec 2026 (estimated) May already have reported ↗
- New study tracks heart disease in rare genetic disorder Results expected Sep 2027 (estimated)
-
Can a single gene fix a fatal heart condition? a trial aims to find out
Cure Recruiting nowThis phase 2 trial tests whether a single dose of LX2006 gene therapy can improve heart muscle thickening and damage in people with Friedreich ataxia, a genetic disorder that often leads to life-threatening cardiomyopathy. Participants aged 6 and older with confirmed heart enlarg…
Phase 2 • Sponsor: Lexeo Therapeutics • Aim: Cure
Last updated Sep 04, 2026 00:00 UTC
-
New study tracks heart disease in rare genetic disorder
Knowledge-focused Recruiting nowThis study follows 65 people with Friedreich ataxia who also have a thickened heart muscle (cardiomyopathy). Researchers will measure changes in heart structure over time using imaging. The goal is to better understand how heart disease progresses in this condition, which could h…
Sponsor: Lexeo Therapeutics • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC